Crafting The Vision: How Early-Stage Biotechs Can Build A Compelling Value Story

By Meg Hooton, President, IQVIA Biotech, Todd Matthews, MBA, Senior Director, Corporate Alliances, IQVIA, and Dean Giovanniello, RPH, MBA, Sr. Principal, Financial Institutions & Brand and Commercial Strategy Consulting Services, IQVIA

For early-stage biotechs, a compelling value story is more than a pitch — it’s the foundation for attracting investors, partners, and talent. Building this narrative requires clarity on scientific differentiation, market potential, and long-term vision. Investors look for more than breakthrough science; they want confidence in scalability, regulatory readiness, and commercial viability.

A strong value story connects these elements into a cohesive message that resonates with stakeholders and positions the company as a credible innovator. Key steps include defining unmet needs, articulating how your solution addresses them, and demonstrating realistic milestones backed by data. Incorporating patient impact and societal benefit can further strengthen the narrative.

Explore practical strategies for crafting a vision that inspires confidence and accelerates growth in a competitive biotech landscape. Access the full resource to learn how to transform your science into a story that drives engagement and investment.